ACE2 and breast cancer: As shown in Fig. 9B, among breast cancer patients receiving chemotherapy, both recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were significantly lower in patients with high ACE2 expression than in those with low expression.